trending Market Intelligence /marketintelligence/en/news-insights/trending/pyhl6862skmsbsovpq2bxa2 content esgSubNav
In This List

Gilead Sciences licenses California-based company's drug discovery technology

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation

Blog

Using Credit Analytics to Avoid Mispricing Insurance Premiums

Blog

Post-Webinar Q&A: Integrating Climate Risks into Credit Risk Portfolios


Gilead Sciences licenses California-based company's drug discovery technology

Gilead Sciences Inc. said it entered a license agreement with San Francisco-based Trianni Inc. to use its drug discovery platform.

The financial details of the agreement were not disclosed in a Sept. 4 news release.

Trianni's transgenic human monoclonal antibody discovery platform uses genetically engineered mice to generate antibodies that can be effective in humans.